These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CALIFORNIA | 94-2424084 | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
| 400 KATO TERRACE | ||
| FREMONT, CA | 94539 | |
| (Address of principal executive offices) | (Zip Code) |
| Large accelerated filer | o | Accelerated filer | o | |
| Non-accelerated filer | o | Smaller reporting company | þ | |
|
(Do not check if a smaller reporting company)
|
| PART I. | FINANCIAL INFORMATION | ||
| ITEM 1. |
Condensed Consolidated Financial Statements (Unaudited)
|
3 | |
| Condensed Consolidated Balance Sheets as of February 28, 2014 and May 31, 2013 | 3 | ||
| Condensed Consolidated Statements of Operations for the three a nd nine months ended February 28, 2014 and 2013 | 4 | ||
| Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended February 28, 2014 and 2013 | 5 | ||
| Condensed Consolidated Statements of Cash Flows for the nine months ended February 28, 2014 and 2013 | 6 | ||
| Notes to Condensed Consolidated Financial Statements | 7 | ||
| ITEM 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 16 | |
| ITEM 3. | Quantitative and Qualitative Disclosures about Market Risks | 20 | |
| ITEM 4. | Controls and Procedures | 21 | |
| PART II. | OTHER INFORMATION | ||
| ITEM 1. | Legal Proceedings | 22 | |
| ITEM 1A. | Risk Factors | 22 | |
| ITEM 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 29 | |
| ITEM 3. | Defaults Upon Senior Securities | 29 | |
| ITEM 4. | Mine Safety Disclosures | 29 | |
| ITEM 5. | Other Information | 29 | |
| ITEM 6. | Exhibits | 29 | |
| SIGNATURES | 30 | ||
| Index to Exhibits | 31 | ||
|
February 28,
|
May 31,
|
|||||||
|
2014
|
2013
|
|||||||
| (1) | ||||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$ | 1,846 | $ | 2,324 | ||||
|
Accounts receivable, net
|
3,378 | 2,632 | ||||||
|
Inventories
|
5,931 | 5,369 | ||||||
|
Prepaid expenses and other
|
399 | 276 | ||||||
|
Total current assets
|
11,554 | 10,601 | ||||||
|
Property and equipment, net
|
311 | 301 | ||||||
|
Other assets
|
78 | 73 | ||||||
|
Total assets
|
$ | 11,943 | $ | 10,975 | ||||
|
LIABILITIES AND SHAREHOLDERS' EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Line of credit
|
$ | 406 | $ | 1,101 | ||||
|
Acounts payable
|
2,265 | 1,188 | ||||||
|
Accrued expenses
|
1,447 | 1,440 | ||||||
|
Customer deposits and deferred revenue, short-term
|
1,345 | 1,972 | ||||||
|
Total current liabilities
|
5,463 | 5,701 | ||||||
|
Income tax payable
|
77 | 109 | ||||||
|
Deferred lease commitment
|
32 | 103 | ||||||
|
Deferred revenue, long-term
|
8 | 68 | ||||||
|
Total liabilities
|
5,580 | 5,981 | ||||||
|
Aehr Test Systems shareholders' equity:
|
||||||||
|
Common stock, $0.01 par value:
Authorized: 75,000 shares;
|
||||||||
| Issued and outstanding: 11,018 shares and 10,599 shares at February 28, 2014 and | ||||||||
|
May 31, 2013, respectively
|
110 | 106 | ||||||
|
Additional paid-in capital
|
51,703 | 50,580 | ||||||
|
Accumulated other comprehensive income
|
2,502 | 2,442 | ||||||
|
Accumulated deficit
|
(47,931 | ) | (48,114 | ) | ||||
|
Total Aehr Test Systems shareholders' equity
|
6,384 | 5,014 | ||||||
|
Noncontrolling interest
|
(21 | ) | (20 | ) | ||||
|
Total shareholders' equity
|
6,363 | 4,994 | ||||||
|
Total liabilities and shareholders' equity
|
$ | 11,943 | $ | 10,975 | ||||
|
(1)
|
The condensed consolidated balance sheet at May 31, 2013 has been derived from the audited consolidated financial statements at that date.
|
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
|
February 28,
|
February 28,
|
|||||||||||||||
|
2014
|
2013
|
2014
|
2013
|
|||||||||||||
|
Net sales
|
$ | 5,612 | $ | 3,340 | $ | 14,314 | $ | 13,226 | ||||||||
|
Cost of sales
|
2,742 | 2,575 | 7,006 | 7,742 | ||||||||||||
|
Gross profit
|
2,870 | 765 | 7,308 | 5,484 | ||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Selling, general and administrative
|
1,701 | 1,511 | 4,638 | 5,368 | ||||||||||||
|
Research and development
|
907 | 685 | 2,386 | 2,577 | ||||||||||||
|
Total operating expenses
|
2,608 | 2,196 | 7,024 | 7,945 | ||||||||||||
|
Income (loss) from operations
|
262 | (1,431 | ) | 284 | (2,461 | ) | ||||||||||
|
Interest expense
|
(7 | ) | (18 | ) | (21 | ) | (43 | ) | ||||||||
|
Other expense, net
|
(21 | ) | (9 | ) | (85 | ) | (43 | ) | ||||||||
|
Income (loss) before income tax
(expense) benefit
|
234 | (1,458 | ) | 178 | (2,547 | ) | ||||||||||
|
Income tax (expense) benefit
|
(22 | ) | -- | 5 | (18 | ) | ||||||||||
|
Net income (loss)
|
212 | (1,458 | ) | 183 | (2,565 | ) | ||||||||||
|
Less: Net income attributable
to the noncontrolling interest
|
-- | -- | -- | -- | ||||||||||||
|
Net income (loss) attributable to Aehr
Test Systems common shareholders
|
$ | 212 | $ | (1,458 | ) | $ | 183 | $ | (2,565 | ) | ||||||
|
Net income (loss) per share – basic
|
$ | 0.02 | $ | (0.16 | ) | $ | 0.02 | $ | (0.28 | ) | ||||||
|
Net income (loss) per share – diluted
|
$ | 0.02 | $ | (0.16 | ) | $ | 0.02 | $ | (0.28 | ) | ||||||
|
Shares used in per share calculations:
|
||||||||||||||||
|
Basic
|
10,982 | 9,363 | 10,807 | 9,276 | ||||||||||||
|
Diluted
|
12,277 | 9,363 | 11,583 | 9,276 | ||||||||||||
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
|
February 28,
|
February 28,
|
|||||||||||||||
|
2014
|
2013
|
2014
|
2013
|
|||||||||||||
|
Net income (loss)
|
$ | 212 | $ | (1,458 | ) | $ | 183 | $ | (2,565 | ) | ||||||
|
Other comprehensive income (loss), net of tax:
Foreign currency translation gain (loss)
|
14 | (13 | ) | 60 | 11 | |||||||||||
|
Total comprehensive income (loss)
|
226 | (1,471 | ) | 243 | (2,554 | ) | ||||||||||
|
Less: Comprehensive loss attributable to
noncontrolling interest
|
-- | -- | (1 | ) | -- | |||||||||||
|
Comprehensive income (loss), attributable to
Aehr Test Systems
|
$ | 226 | $ | (1,471 | ) | $ | 242 | $ | (2,554 | ) | ||||||
|
Nine Months Ended
|
||||||||
|
February 28,
|
||||||||
|
2014
|
2013
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Net income (loss)
|
$ | 183 | $ | (2,565 | ) | |||
|
Adjustments to reconcile net income (loss) to
net cash used in operating activities:
|
||||||||
|
Stock-based compensation expense
|
625 | 427 | ||||||
|
Provision for (recovery of) doubtful accounts
|
13 | (15 | ) | |||||
|
Gain on disposal of fixed asset
|
(41 | ) | -- | |||||
|
Depreciation and amortization
|
119 | 247 | ||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable
|
(685 | ) | 951 | |||||
|
Inventories
|
(546 | ) | 375 | |||||
|
Prepaid expenses and other
|
(123 | ) | (11 | ) | ||||
|
Accounts payable
|
1,075 | 379 | ||||||
|
Accrued expenses
|
8 | (49 | ) | |||||
|
Customer deposits and deferred revenue
|
(691 | ) | -- | |||||
|
Income tax payable
|
(35 | ) | 15 | |||||
|
Deferred lease commitment
|
(71 | ) | (57 | ) | ||||
|
Net cash used in
operating activities
|
(169 | ) | (303 | ) | ||||
|
Cash flows from investing activities:
|
||||||||
|
Purchases of property and equipment
|
(154 | ) | (126 | ) | ||||
|
Proceeds from sales of property and equipment
|
50 | -- | ||||||
|
Net cash used in investing activities
|
(104 | ) | (126 | ) | ||||
|
Cash flows from financing activities:
|
||||||||
|
Line of credit repayments, net
|
(695 | ) | (193 | ) | ||||
|
Proceeds from issuance of common stock
and exercise of stock options
|
502 | 180 | ||||||
|
Net cash used in
financing activities
|
(193 | ) | (13 | ) | ||||
|
Effect of exchange rates on cash
|
(12 | ) | (250 | ) | ||||
|
Net decrease in cash and
cash equivalents
|
(478 | ) | (692 | ) | ||||
|
Cash and cash equivalents, beginning of period
|
2,324 | 2,073 | ||||||
|
Cash and cash equivalents, end of period
|
$ | 1,846 | $ | 1,381 | ||||
|
Supplemental disclosure of non-cash flow information:
|
||||||||
|
Net change in capitalized share-based compensation
|
$ | -- | $ | 25 | ||||
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
|
February 28,
|
February 28,
|
|||||||||||||||
|
2014
|
2013
|
2014
|
2013
|
|||||||||||||
|
Stock-based compensation in the form of employee stock options and ESPP shares, included in:
|
||||||||||||||||
|
Cost of sales
|
$ | 10 | $ | 9 | $ | 33 | $ | 26 | ||||||||
|
Selling, general and administrative
|
184 | 159 | 471 | 315 | ||||||||||||
|
Research and development
|
41 | 33 | 121 | 86 | ||||||||||||
|
Total stock-based compensation
|
$ | 235 | $ | 201 | $ | 625 | $ | 427 | ||||||||
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||
|
February 28,
|
February 28,
|
|||||||||||||
|
2013
|
2014
|
2013
|
||||||||||||
|
Option plan shares
|
||||||||||||||
|
Expected term (in years)
|
5 | 4 | 5 | |||||||||||
|
Volatility
|
0.94 | 0.95 | 0.91 | |||||||||||
|
Expected dividend
|
$0.00 | $0.00 | $0.00 | |||||||||||
|
Risk-free interest rates
|
0.76 | % | 1.40 | % | 0.72 | % | ||||||||
|
Estimated forfeiture rate
|
0.25 | % | 0.25 | % | 0.25 | % | ||||||||
|
Weighted average grant date fair value
|
$0.62 | $1.03 | $0.78 | |||||||||||
|
Nine Months Ended
|
|||||
|
February 28,2014
|
|||||
|
Employee stock purchase plan purchase rights
|
|||||
|
Expected term (in years)
|
0.5-2.0 | ||||
|
Volatility
|
0.86-1.00 | ||||
|
Expected dividend
|
$ | 0.00 | |||
|
Risk-free interest rates
|
0.04%-0.33 | % | |||
|
Estimated forfeiture rate
|
0 | % | |||
|
Weighted average grant date fair value
|
$ | 1.34 | |||
|
Outstanding Options
|
||||||||||||||||
|
Weighted
|
||||||||||||||||
|
Number
|
Average
|
Aggregate
|
||||||||||||||
|
Available
|
of
|
Exercise
|
Intrinsic
|
|||||||||||||
|
Shares
|
Shares
|
Price
|
Value
|
|||||||||||||
|
Balances, May 31, 2013
|
1,737 | 2,956 | $ | 1.79 | $ | 964 | ||||||||||
|
Options granted
|
(725 | ) | 725 | $ | 1.38 | |||||||||||
|
Options terminated
|
289 | (289 | ) | $ | 6.99 | |||||||||||
|
Plan shares expired
|
(104 | ) | -- | |||||||||||||
|
Options exercised
|
-- | (69 | ) | $ | 0.86 | |||||||||||
|
Balances, August 31, 2013
|
1,197 | 3,323 | $ | 1.27 | $ | 1,301 | ||||||||||
|
Options granted
|
(107 | ) | 107 | $ | 2.68 | |||||||||||
|
Options terminated
|
131 | (131 | ) | $ | 2.26 | |||||||||||
|
Options exercised
|
-- | (149 | ) | $ | 1.71 | |||||||||||
|
Balances, November 30, 2013
|
1,221 | 3,150 | $ | 1.25 | $ | 4,968 | ||||||||||
|
Options granted
|
-- | -- | ||||||||||||||
|
Options terminated
|
-- | -- | ||||||||||||||
|
Options exercised
|
-- | (85 | ) | $ | 0.93 | |||||||||||
|
Balances, February 28, 2014
|
1,221 | 3,065 | $ | 1.26 | $ | 3,370 | ||||||||||
|
Options fully vested and expected to
vest at February 28, 2014
|
3,004 | $ | 1.26 | $ | 3,303 | |||||||||||
|
Options exercisable at February 28, 2014
|
1,852 | $ | 1.21 | $ | 2,051 | |||||||||||
|
Options Outstanding
|
Options Exercisable
|
||||||||||||||||||||||||||
|
at February 28, 2014
|
at February 28, 2014
|
||||||||||||||||||||||||||
|
Range of Exercise
Prices
|
Number
Outstanding
Shares
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
Weighted
Average
Exercise Price
|
Number
Exercisable
Shares
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
Weighted
Average
Exercise Price
|
Aggregate
Intrinsic
Value
|
||||||||||||||||||||
| $ | 0.59-$0.97 | 1,000 | 3.76 | $ | 0.75 | 804 | 3.50 | $ | 0.79 | ||||||||||||||||||
| $ | 1.09-$1.42 | 1,442 | 5.11 | $ | 1.28 | 585 | 4.37 | $ | 1.29 | ||||||||||||||||||
| $ | 1.73-$1.95 | 461 | 3.05 | $ | 1.88 | 361 | 2.47 | $ | 1.91 | ||||||||||||||||||
| $ | 2.15-$2.68 | 162 | 4.83 | $ | 2.50 | 102 | 4.00 | $ | 1.57 | ||||||||||||||||||
| $ | 0.59-$2.68 | 3,065 | 4.35 | $ | 1.26 | 1,852 | 3.60 | $ | 1.21 |
$ 2,051
|
|||||||||||||||||
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
|
February 28,
|
February 28,
|
|||||||||||||||
|
2014
|
2013
|
2014
|
2013
|
|||||||||||||
|
Numerator: Net income (loss)
|
$ | 212 | $ | (1,458 | ) | $ | 183 | $ | (2,565 | ) | ||||||
|
Denominator for basic net income (loss)
per share:
|
||||||||||||||||
|
Weighted-average shares outstanding
|
10,982 | 9,363 | 10,807 | 9,276 | ||||||||||||
| Shares used in basic net income (loss) per share calculation | 10,982 | 9,363 | 10,807 | 9,276 | ||||||||||||
|
Effect of dilutive securities
|
1,295 | -- | 776 | -- | ||||||||||||
|
Denominator for diluted net income (loss)
per share
|
12,277 | 9,363 | 11,583 | 9,276 | ||||||||||||
|
Basic net income (loss) per share
|
$ | 0.02 | $ | (0.16 | ) | $ | 0.02 | $ | (0.28 | ) | ||||||
|
Diluted net income (loss) per share
|
$ | 0.02 | $ | (0.16 | ) | $ | 0.02 | $ | (0.28 | ) | ||||||
|
Balance as of
|
||||||||||||||||
|
February 28, 2014
|
Level 1
|
Level 2
|
Level 3
|
|||||||||||||
|
Money market funds
|
$ | 452 | $ | 452 | $ | -- | $ | -- | ||||||||
|
Assets
|
$ | 452 | $ | 452 | $ | -- | $ | -- | ||||||||
|
Liabilities
|
$ | -- | $ | -- | $ | -- | $ | -- | ||||||||
|
Balance as of
|
||||||||||||||||
|
May 31, 2013
|
Level 1
|
Level 2
|
Level 3
|
|||||||||||||
|
Money market funds
|
$ | 102 | $ | 102 | $ | -- | $ | -- | ||||||||
|
Assets
|
$ | 102 | $ | 102 | $ | -- | $ | -- | ||||||||
|
Liabilities
|
$ | -- | $ | -- | $ | -- | $ | -- | ||||||||
|
February 28,
|
May 31,
|
|||||||
|
2014
|
2013
|
|||||||
|
Raw materials and sub-assemblies
|
$ | 2,920 | $ | 3,180 | ||||
|
Work in process
|
3,011 | 2,187 | ||||||
|
Finished goods
|
-- | 2 | ||||||
| $ | 5,931 | $ | 5,369 | |||||
|
United
|
||||||||||||||||
|
States
|
Asia
|
Europe
|
Total
|
|||||||||||||
|
Three months ended February 28, 2014:
|
||||||||||||||||
|
Net sales
|
$ | 2,863 | $ | 1,039 | $ | 1,710 | $ | 5,612 | ||||||||
|
Property and equipment, net
|
268 | 42 | 1 | 311 | ||||||||||||
|
Nine months ended February 28, 2014:
|
||||||||||||||||
|
Net sales
|
$ | 7,082 | $ | 4,963 | $ | 2,269 | $ | 14,314 | ||||||||
|
Property and equipment, net
|
268 | 42 | 1 | 311 | ||||||||||||
|
Three months ended February 28, 2013:
|
||||||||||||||||
|
Net sales
|
$ | 2,100 | $ | 1,188 | $ | 52 | $ | 3,340 | ||||||||
|
Property and equipment, net
|
321 | 57 | -- | 378 | ||||||||||||
|
Nine months ended February 28, 2013:
|
||||||||||||||||
|
Net sales
|
$ | 6,095 | $ | 6,546 | $ | 585 | $ | 13,226 | ||||||||
|
Property and equipment, net
|
321 | 57 | -- | 378 | ||||||||||||
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
|
February 28,
|
February 28,
|
|||||||||||||||
|
2014
|
2013
|
2014
|
2013
|
|||||||||||||
|
Balance at the beginning of the period
|
$ | 208 | $ | 174 | $ | 222 | $ | 91 | ||||||||
|
Accruals for warranties issued during the period
|
34 | 162 | 188 | 412 | ||||||||||||
|
Settlement made during the period (in cash or in kind)
|
(46 | ) | (139 | ) | (214 | ) | (306 | ) | ||||||||
| Balance at the end of the period | $ | 196 | $ | 197 | $ | 196 | $ | 197 | ||||||||
|
February 28,
|
May 31,
|
|||||||
|
2014
|
2013
|
|||||||
|
Customer deposits
|
$ | 1,158 | $ | 1,728 | ||||
|
Deferred revenue, short-term
|
187 | 244 | ||||||
| $ | 1,345 | $ | 1,972 | |||||
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
|
February 28,
|
February 28,
|
|||||||||||||||
|
2014
|
2013
|
2014
|
2013
|
|||||||||||||
|
Net sales
|
100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | ||||||||
|
Cost of sales
|
48.9 | 77.1 | 48.9 | 58.5 | ||||||||||||
|
Gross profit
|
51.1 | 22.9 | 51.1 | 41.5 | ||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Selling, general and administrative
|
30.3 | 45.2 | 32.4 | 40.6 | ||||||||||||
|
Research and development
|
16.2 | 20.5 | 16.7 | 19.5 | ||||||||||||
|
Total operating expenses
|
46.5 | 65.7 | 49.1 | 60.1 | ||||||||||||
|
Income (loss) from operations
|
4.6 | (42.8 | ) | 2.0 | (18.6 | ) | ||||||||||
|
Interest expense
|
(0.1 | ) | (0.6 | ) | (0.1 | ) | (0.4 | ) | ||||||||
|
Other expense, net
|
(0.3 | ) | (0.3 | ) | (0.6 | ) | (0.3 | ) | ||||||||
|
Income (loss) before income tax
(expense) benefit
|
4.2 | (43.7 | ) | 1.3 | (19.3 | ) | ||||||||||
|
Income tax (expense) benefit
|
(0.4 | ) | -- | -- | (0.1 | ) | ||||||||||
|
Net income (loss)
|
3.8 | (43.7 | ) | 1.3 | (19.4 | ) | ||||||||||
|
Less: Net income attributable to
the noncontrolling interest
|
-- | -- | -- | -- | ||||||||||||
|
Net income (loss) attributable to
Aehr Test Systems common shareholders
|
3.8 | % | (43.7 | )% | 1.3 | % | (19.4 | )% | ||||||||
| Aehr Test Systems | |||
| (Registrant) | |||
|
Date: April 11, 2014
|
By:
|
/s/ GAYN ERICKSON | |
| Gayn Erickson | |||
| President and Chief Executive Officer | |||
|
Date: April 11, 2014
|
By:
|
/s/ GARY L. LARSON | |
| Gary L. Larson | |||
| Vice President of Finance and Chief Financial Officer | |||
| Exhibit No. | Description | |
| 3.1(1) | Restated Articles of Incorporation of the Company. | |
| 3.2(2) | Amended and Restated Bylaws of the Company. | |
| 31.1 | Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002. | |
| 31.2 | Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002. | |
| 32.1 | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* | |
| 101.INS | XBRL Instance Document | |
| 101.SCH | XBRL Taxonomy Extension Schema Document | |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|